Interleukin-36 alpha (IL-36α) is a pro-inflammatory cytokine belonging to the IL-1 superfamily that plays a pivotal role in epithelial barrier immunity and inflammatory diseases.
Encoded by the IL36A gene on chromosome 2, IL-36α is a 158-amino acid protein with a molecular weight of approximately 17.7 kDa. Structurally, it adopts a characteristic ß-trefoil fold typical of the IL-1 family. It is synthesized as an inactive cytoplasmic precursor lacking a conventional signal peptide. To become fully active, it must undergo post-translational, proteolytic N-terminal truncation by extracellular neutrophil proteases (such as elastase and cathepsin G), which enhances its pro-inflammatory activity up to 10,000-fold.
IL-36α acts as a potent agonist ligand. Upon activation, it binds to the specific IL-36 receptor (IL-36R) on target cells. This binary interaction recruits the shared co-receptor IL-1 receptor accessory protein (IL-1RAcP), forming a functional heterotrimeric signaling complex. Intracellularly, this recruits the adaptor protein MyD88, triggering the NF-κB and MAPK signaling cascades. Predominantly expressed in epithelial barriers like skin keratinocytes, IL-36α induces the production of downstream chemokines (e.g., CXCL8, CCL20) and cytokines (e.g., IL-6, TNF-α). This response bridges innate and adaptive immunity by driving dendritic cell maturation, neutrophil infiltration, and T-cell proliferation.
Dysregulation of IL-36α signaling is strongly implicated in chronic inflammatory and autoimmune pathologies. It is a primary driver in generalized pustular psoriasis (GPP), plaque psoriasis, and inflammatory bowel disease (IBD). Consequently, the IL-36 pathway has become a major therapeutic target. Monoclonal antibodies targeting the IL-36R, such as spesolimab (FDA-approved) and imsidolimab, function as allosteric antagonists to block agonist binding, providing highly effective management for severe inflammatory flare-ups like GPP. Additionally, its altered expression serves as a potential biomarker for disease severity in rheumatoid arthritis and certain mucosal malignancies.




Reviews
There are no reviews yet.